The first-line question in metastatic urothelial cancer is becoming easier. The second-line question is getting harder.
EV + pembrolizumab, if available, changed the algorithm. Now we need to define what comes next.
@OncoAlert@Uromigos@OpenMedicineHQ@myESMO